Fig. 6

CaMKII mediates the synergistic relaxation from the combination of β2AR agonist with ANO1 blockade in precontracted human USM strips. Compiled data illustrate percentage of reduction in integral force (g*sec) from baseline oxytocin-induced contractility between treatment groups. Results were normalized to the control and reported as mean ± SEM. We observed no change with CaMKII Inhibitor XII (1 µM) alone, and again see statistically significant potentiation of relaxation with low-dose TRB + BB versus control. Interestingly, pretreatment with CaMKII Inhibitor XII mitigated the relaxation associated with the combination of TRB and BB (*p < 0.05, ***p < 0.001; n = 48 from 7 different patients)